MX2007006059A - Composition for removal of skin pigmentation. - Google Patents
Composition for removal of skin pigmentation.Info
- Publication number
- MX2007006059A MX2007006059A MX2007006059A MX2007006059A MX2007006059A MX 2007006059 A MX2007006059 A MX 2007006059A MX 2007006059 A MX2007006059 A MX 2007006059A MX 2007006059 A MX2007006059 A MX 2007006059A MX 2007006059 A MX2007006059 A MX 2007006059A
- Authority
- MX
- Mexico
- Prior art keywords
- skin
- hydroquinone
- composition
- tretinoin
- acne
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 208000012641 Pigmentation disease Diseases 0.000 title abstract description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000006071 cream Substances 0.000 claims abstract description 24
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 19
- 206010000496 acne Diseases 0.000 claims abstract description 16
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims abstract description 13
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 208000003351 Melanosis Diseases 0.000 claims abstract description 5
- 206010008570 Chloasma Diseases 0.000 claims abstract description 4
- 239000002884 skin cream Substances 0.000 claims abstract description 3
- 229960004703 clobetasol propionate Drugs 0.000 claims abstract 3
- 229960001727 tretinoin Drugs 0.000 claims description 17
- 229960002842 clobetasol Drugs 0.000 claims description 10
- 208000031066 hyperpigmentation of the skin Diseases 0.000 claims description 7
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 238000010517 secondary reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000516 sunscreening agent Substances 0.000 abstract description 4
- 208000000069 hyperpigmentation Diseases 0.000 abstract description 3
- 230000003810 hyperpigmentation Effects 0.000 abstract description 3
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 9
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100038503 Cellular retinoic acid-binding protein 1 Human genes 0.000 description 2
- 101001099865 Homo sapiens Cellular retinoic acid-binding protein 1 Proteins 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 101001099854 Xenopus laevis Cellular retinoic acid-binding protein 2 Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000347881 Kadua laxiflora Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The present invention is related to skin creams in general, and specifically to a cream composition for removal of skin pigmentation acting as a topical melanin reducing agent for the treatment of hyperchromia, chloasma and acne, which gradually reduces the hyperpigmentation of skin and acne in a short term showing satisfactory results without side effects. The inventive composition is characterised in that it comprises tretinoine, clobetasol propionate, hydroquinone, and excipients with or without a sun screen agent; the invention quantitatively comprises 0.050 gr of tretinoine, 0.044 gr of clobetasol propionate, 4.100 gr of hydroquinone and 100 gr of c.b.p. excipient.
Description
COMPOSITION OF SKIN DETACHING CREAM FIELD OF THE INVENTION
The present invention relates to skin creams in general, in particular with a skin-removing cream composition as topical demeaning agent for the treatment of hyperchromias, chloasma and acne, which gradually reduces hyperpigmetation of the skin.
BACKGROUND OF THE INVENTION
Currently the cosmetic industry in terms of skin care has had a great development, so the topical creams for the face and body have made great progress not only in terms of cleaning and moisturizing the skin, but also in the prevention, treatment and elimination of hyperpigmentation of the skin due to the localized or generalized increase of melanin pigmentation whose causes can be endocrine, metabolic, by drugs; in conditions such as chloasma, residual hyperchromias of inflammatory processes, drug or chemical photosensitization, cosmetic, senile lentigo and freckles.
?
For example, there are some topical creams on the market that try to eliminate hyperpigmentation of the skin, which base their composition on hydroquinone with some sunscreen agent; hydroquinone whose chemical name is 1,4-dihydroxybenzene, is also known as p-dioxobenzene, 1,4 p-benzenediol, hydroquinol, quinol or teequinol, is the substance used as an active ingredient for the production of skin whitening agents more common in the world. Within the health hazards, hydroquinone has been classified as "toxic" by direct ingestion, and as "noxious" by contact with eyes, skin and inhalation in large doses.
Acne treatment creams have also been developed that try to keep the exit orifices of the sebaceous glands free for the expulsion of the comedones.
However, existing creams on the market offer long-term results, since hydroquinone has difficulty penetrating the stratum corneum of the epidermis, delaying its arrival in the basal stratum of the epidermis where the melanocytes that cause hyperpigmentation are accumulated. makes treatments expensive and time consuming; In addition, the results are poor and generate secondary reactions such as irritation, burning, inflammation, etc.
Seeing the need to offer a highly effective topical application cream for the elimination of hyperpigmentation of the skin in a short period of time with satisfactory results and without secondary reactions, it was that the composition of skin-removing cream was developed, in accordance with the present description.
OBJECTIVES OF THE INVENTION
The main objective of the present invention is to provide a novel composition of skin-removing cream for the elimination of hyperpigmentation of the skin and of acne, in the short term with satisfactory results and without secondary reactions.
Another objective of the invention is to allow said novel composition of skin-removing cream, which also removes the stained scars of the skin caused by acne.
A further objective of the present invention is to make available said novel composition of skin-removing cream, which also improves the clinical image of the skin.
Another object of the invention is to allow said composition
Novelty of skin-removing cream, which also in the case of acne, prevents the formation of comedones and allows the expulsion of existing ones by keeping the pilo-sebaceous ducts free.
Still another objective of the invention is to allow said novel composition of skin-removing cream, which also stimulates the metabolic activity of the epidermis to allow a keratinization modulation, accelerate cell renewal and desquamation of cells of the stratum corneum.
And all those qualities and objectives that will become apparent when making a general and detailed description of the present invention supported by the illustrated modalities.
BRIEF DESCRIPTION OF THE INVENTION
Generally speaking, the skin-removing cream according to the present invention has a composition Tretinoin, Clobetasol Propanate, Hydroquinone and an excipient, which may or may not include a sunscreen.
During the formulation of the cream, average concentrations were used both in the use of tretinoin and in the
of hydroquinone at a dose of 2% with an effect is very slight and at concentrations greater than 5% with undesirable effects, so it was decided to use it at 3% and then at 4%, obtaining better results with the latter. In tretinoin, 0.050% was used with good results, clobetasol was used at therapeutic doses. Thus some formulations were used like the following.
1) Tretinoin 0.050%, Hydroquinone 4.1 gr., Clobetasol .044 gr. 2) Tretinoin 0.050%, Hydroquinone 3 gr., Clobetasol .044 gr.
Quantitatively, the preferred composition of the invention consists of every 100 mg. of cream: • Tretinoin 0.050 gr. · Clobetasol Propyanate equivalent to 0.044 gr. Hydroquinone 4.100 g r.; Y
«Excipient c.b.p. 100 grs.
As is known, melanin is a pigment that is formed in the melanosomes of cells called melanocytes, these cells are found among the keratinocytes of the basal layer of the epidermis, which is the deepest of this; the melanocytes have dendrites or branches that disperse between the keratinocytes and lead their pigment (melanin) to the surface of the skin. Melanosomes synthesize melanin,
by tyrosine, which is transformed to melanin, by means of an enzyme called tyrosinase
Hydroquinone, are used to reduce hyperpigmentation of the skin, since it is a topical demelanizing, its topical application depletes melanin deposits and prevents the synthesis of melanin, inhibiting the tyrosinase enzyme that transforms tyrosine into melanin. Exposure to sunlight reduces the depigmenting effect of hydroquinone so that repigmentation can occur, so when using hydroquinone, exposure to the rays of the sun alone or using a sunscreen should be avoided.
As is known, the epidermis has several layers or layers, of which the most superficial is the corneal layer or stratum corneum. The stratum corneum is formed by rows of dead cells, which no longer have a nucleus and are dehydrated. These small cells contain keratin and fat inside; the tretinoin that is a keratolytic, breaks the keratin achieving a thinning of the stratum corneum and with this a more soft and radiant skin appearance, also accelerates the normal desquamation of the cells of the cornea layer, to achieve this, the tretinoin penetrates the cellular cytoplasm by means of a specific transporter, or CRABP, to which it is linked. The penetration in the nucleus is always done thanks to the transport by the CRABP and the acid vitamin A is linked, in the nucleus, to a specific receptor called
Retinoic acid receptor or RAR, which allows its attachment to DNA at a specific site, thereby influencing the synthesis of proteins of the cell's cytoskeleton (keratin, etc.). At the epidermal level this allows a modulation of the q uera ti n ization, acceleration of cell renewal, acceleration of desquamation of corneal layer cells, etc.
Tretinoin It is used as an adjuvant in the treatment of acne, in acne, the glands are stimulated by androgens and increases their secretion of sebum .; at the same time, and due to an unknown cause, some sebaceous glands increase their follicular keratinization at the level of the infundibulum, which leads to an obstruction in the exit channel of the sebaceous gland. In this way, sebum begins to accumulate inside the gland; the process continues and the sebaceous gland grows accumulating this secretion of sebum to form a large sac called comedon. Tretinoin decreases the hyperkeratinization of the exit duct of the sebaceous gland, it is keratolytic, so it helps to keep the sebaceous glands free and also accelerates the release of old cells from the superficial layers, favoring the expulsion of comedones.
With regard to clobetasol, which is a topical corticosteroid which has a mainly anti-inflammatory effect,
antipruritic and vasoconstrictor.
Thus, the three components consisting of Clobetasol Propyanate, Hydroquinone, and Tretinoin, exert their properties each, but as the main effect for which this cream is used is to remove the face or diminish areas of hyperpigmentation, this composition what it does is that tretinoin increases the penetration effect of hydroquinone, which will make the effect stronger and faster, the corticoid was added since tretinoin and hydroquinone have a common side effect that is irritation and with the Corticoid help is about limiting this effect.
The cream, according to the composition described above, has great advantages such as those mentioned below:
Reduces areas of hyperpigmentation of the skin. Improves the clinical image of the skin. It helps to avoid new injuries and eliminate existing ones. In case of acne, avoid the formation of comedones and allow the expulsion of existing ones, as well as helping to keep sebaceous pilo ducts free, and with all this help the self-esteem of patients.
The invention has been sufficiently described so that a person with average skill in the art can reproduce and obtain the results that we mentioned in the present invention. However, any person skilled in the art who is competent in the present invention may be able to make modifications not described in the present application, however, if for the application of these modifications in a certain structure or in the manufacturing process thereof, the subject matter claimed in the following claims is required, said structures should be understood within the scope of the invention.
Claims (4)
1. - A composition of skin-removing cream characterized by comprising tretinoin, propylate of clobetasol, hydroquinone and an excipient,
2. - A composition of skin-removing cream, according to claim 1, further characterized by comprising a sun blocking agent.
3. - A skin-removing cream composition, according to claim 1, characterized in that the hydroquinone is used in doses of 2% to 5%.
4. - A skin-removing cream composition, according to claim 1, characterized in that it quantitatively comprises: Tretinoin 0.050 gr. Clobetasol propionate equivalent to 0.044 gr. and Hydroquinone 4.100 g r.; Y »Excipient c.b.p. 100 grs. SUMMARY The present invention is related to skin creams in general, in particular with a skin-removing cream composition as topical demeaning agent for the treatment of hyperchromias, chloasma and acne, which gradually reduces the hyperpigmetation of the skin; whose objective is the elimination of hyperpigmentation of the skin and acne, in a short term with satisfactory results and without secondary reactions; which is characterized by comprising tretinoin, clobetasol propyanate, hydroquinone and an excipient, with or without some sun blocking agent and quantitatively comprises preferably 0.050 gr. of tretinoin, 0.044 gr. of propianate of clobetasol, 4.100 gr. of hydroquinone and excipient c.b.p. 100 grs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007006059A MX2007006059A (en) | 2007-05-21 | 2007-05-21 | Composition for removal of skin pigmentation. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007006059A MX2007006059A (en) | 2007-05-21 | 2007-05-21 | Composition for removal of skin pigmentation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007006059A true MX2007006059A (en) | 2009-02-25 |
Family
ID=41127700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007006059A MX2007006059A (en) | 2007-05-21 | 2007-05-21 | Composition for removal of skin pigmentation. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2007006059A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361350A1 (en) * | 2009-12-04 | 2011-06-16 | Julio Monje Diaz | Eliminating cream of hyperpigmentary spots for the skin of the face and its utilization. (Machine-translation by Google Translate, not legally binding) |
-
2007
- 2007-05-21 MX MX2007006059A patent/MX2007006059A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361350A1 (en) * | 2009-12-04 | 2011-06-16 | Julio Monje Diaz | Eliminating cream of hyperpigmentary spots for the skin of the face and its utilization. (Machine-translation by Google Translate, not legally binding) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240016880A1 (en) | Compositions and methods for invasive and non-invasive procedural skincare | |
| JP5570992B2 (en) | Method and composition for treating skin diseases or skin lesions | |
| Vashi et al. | Facial hyperpigmentation: causes and treatment | |
| US6008254A (en) | Method of treating skin disorders with high-strength tretinoin | |
| JP6257518B2 (en) | Composition for skin exfoliation and use thereof | |
| BR112020002222A2 (en) | compositions and methods for improving sagging skin and body contour | |
| JP2012515218A (en) | Calcium sequestration compositions and methods for treating skin pigmentation disorders and conditions | |
| CA2525465A1 (en) | Topical composition for transdermal administration | |
| EP1527770B1 (en) | A cosmetic mask composition | |
| JP2001019607A (en) | Skin cosmetic | |
| AU2015252207B2 (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
| MX2007006059A (en) | Composition for removal of skin pigmentation. | |
| CN116348099B (en) | Topical formulations | |
| US20110274727A1 (en) | Depigmenting topical compositions and their uses | |
| CN1121850C (en) | Use of unfermented honey as decolouring agent | |
| US20250360068A1 (en) | Topical dim compositions and cosmetic uses thereof | |
| RU2325900C2 (en) | Skin composition of external application | |
| Level et al. | Patient Selection and Analysis Fitzpatrick Classification (Table 21.1) | |
| TWI325324B (en) | ||
| Tedeschi et al. | Chemical peel | |
| Dunwell | Complications in Chemical Peeling of the Dark-Skinned Patient | |
| HK1150155B (en) | Topical compositions for treating inflammatory disorders, diseases and conditions | |
| HK1150155A (en) | Topical compositions for treating inflammatory disorders, diseases and conditions | |
| BRPI1000761A2 (en) | synergistic association for superficial chemical peel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |